Mitsubishi UFJ Trust & Banking Corp Has $246.18 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Mitsubishi UFJ Trust & Banking Corp raised its position in Johnson & Johnson (NYSE:JNJ) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,702,258 shares of the company’s stock after purchasing an additional 3,914 shares during the period. Johnson & Johnson makes up about 0.6% of Mitsubishi UFJ Trust & Banking Corp’s investment portfolio, making the stock its 25th biggest holding. Mitsubishi UFJ Trust & Banking Corp owned about 0.07% of Johnson & Johnson worth $246,181,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Florida Financial Advisors LLC grew its position in shares of Johnson & Johnson by 4.4% in the 4th quarter. Florida Financial Advisors LLC now owns 7,113 shares of the company’s stock valued at $1,029,000 after purchasing an additional 297 shares during the period. Meiji Yasuda Asset Management Co Ltd. raised its holdings in shares of Johnson & Johnson by 0.7% during the fourth quarter. Meiji Yasuda Asset Management Co Ltd. now owns 134,563 shares of the company’s stock worth $19,461,000 after acquiring an additional 915 shares during the period. Bay Capital Advisors LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at $220,000. Potentia Wealth bought a new position in Johnson & Johnson during the 4th quarter worth about $724,000. Finally, PKS Advisory Services LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $436,000. 69.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Morgan Stanley decreased their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Leerink Partners lowered their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Wells Fargo & Company reduced their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Stifel Nicolaus lowered their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Finally, Bank of America increased their price objective on shares of Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research note on Wednesday, March 5th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.1 %

Shares of Johnson & Johnson stock opened at $163.43 on Tuesday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a market capitalization of $393.83 billion, a price-to-earnings ratio of 24.58, a PEG ratio of 2.56 and a beta of 0.47. The firm’s 50-day moving average price is $157.37 and its two-hundred day moving average price is $156.16.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter last year, the business posted $2.29 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.04%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.